---
title: "CMBI Raises SBP GROUP  TP to HKD9 as Multiple Innovative Drugs Included in National Medical Insurance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305913051.md"
description: "CMB International raised SBP GROUP's target price to HKD9 and maintained a 'Buy' rating, citing breakthroughs in innovative drug commercialization and international partnerships. The company's subsidiary had three new drugs added to the National Reimbursement Drug List, while a major BD agreement with Boehringer Ingelheim valued at up to USD7 billion validated its R&D platform. CMBI upgraded revenue and profit forecasts for 2026-2028 based on these positive developments."
datetime: "2026-11-18T04:23:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305913051.md)
  - [en](https://longbridge.com/en/news/305913051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305913051.md)
generator: "portal-rs"
---

# CMBI Raises SBP GROUP  TP to HKD9 as Multiple Innovative Drugs Included in National Medical Insurance

CMB International issued a report stating that SBP GROUP (01177.HK) -0.105 (-1.923%) Short selling $96.10M; Ratio 24.289% has recently continued to achieve breakthroughs in both innovative drug commercialization and internationalization. On 14 Nov 2026, the National Healthcare Security Administration announced the "National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work Injury Insurance (2026)", under which the company's core subsidiary Chia Tai Tianqing had three innovative drugs newly included in the list, additional indications for two innovative drugs included, and successful renewals for two innovative drugs.

The report stated that the company recently also reached a platform-based BD cooperation agreement with multinational pharmaceutical company Boehringer Ingelheim (BI), involving an upfront payment and near-term payments of USD358 million, total potential deal value of approximately USD7 billion, and double-digit sales royalties. The deal continues the strong trend of the company's external cooperation execution in 2026. Expansion of medical insurance coverage is expected to accelerate the commercialization of China Biologic Products' innovative products, while the cooperation with BI validates the value of the company's early-stage R&D platform and strengthens the foundation for long-term growth of its innovative business.

Considering the company's continued execution of BD transactions in 2026, the broker raised its forecasts and expects revenue to grow YoY by 11.5%, 13.2% and 10.4% from 2026 to 2028, while adjusted attributable net profit is expected to grow YoY by 12.5%, 19.4% and 9.9%. It maintained the "Buy" rating and raised the TP from HKD8.7 to HKD9. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Will Cancer Drug Partnership Change Sino Biopharmaceutical's (SEHK:1177) Narrative](https://longbridge.com/en/news/305490163.md)
- [China’s burgeoning novel medicines success presents opportunity for Europe](https://longbridge.com/en/news/305007877.md)
- [SBP GROUP  Reaches Collaboration With Boehringer Ingelheim, Potential Proceeds USD7 Billion](https://longbridge.com/en/news/304243255.md)
- [Sino Biopharm Surges After Striking Over USD7 Billion Cancer Drug Deal With Boehringer Ingelheim](https://longbridge.com/en/news/304378912.md)
- [Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn](https://longbridge.com/en/news/304298771.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**